Covalent K-Ras Modulators for Oncogenic Mutant Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods have been unsuccessful in directly modulating the activity of the K-Ras enzyme, which is frequently mutated in human cancer, leading to a need for effective Ras inhibitors and anticancer compounds.
Innovation Solution
The use of covalent modulators, including reversible or irreversible compounds, to target and modulate the K-Ras protein, specifically designed to bind to oncogenic mutants, thereby reducing their activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to modulate K-Ras activity, then the approach is simple and direct, but the methods have been unsuccessful in achieving effective inhibition
Solution Approach 1:
The modulator is divided into distinct functional segments: an electrophilic warhead (for covalent binding to Cys185), a linker region, and a pharmacophore domain (for non-covalent interactions with the Ras protein). This segmentation allows each part to fulfill its specific function while achieving overall effective inhibition of K-Ras.
Solution Approach 2:
The patent employs a two-stage binding mechanism where the modulator first forms a non-covalent complex with the Ras protein (mediated by the pharmacophore), which then facilitates subsequent covalent bond formation (mediated by the electrophilic warhead). This intermediary non-covalent interaction increases the precision and effectiveness of the final covalent inhibition.
2Reliability
If covalent modulators are used to target K-Ras, then the inhibition effectiveness is improved, but the selectivity and specificity become more challenging
Solution Approach 1:
The modulator exhibits different binding characteristics at different locations on the Ras protein: the electrophilic warhead specifically targets the mutant cysteine residue (Cys185) for covalent modification, while the pharmacophore domain forms non-covalent interactions with the Ras binding domain. This localized differentiation of binding modes enhances both effectiveness and selectivity.
Solution Approach 2:
The patent exploits the specific biochemical parameter change introduced by oncogenic mutations (e.g., G12C, G12V, G12D) that create or expose a cysteine residue at position 185. The electrophilic warhead is designed to react specifically with this mutated cysteine, which is not present or accessible in wild-type Ras, thereby achieving mutation-specific inhibition.
3Object-affected harmful factors
If reversible modulators are used, then the selectivity is improved, but the duration of action is reduced
Solution Approach 1:
The modulator first establishes a non-covalent complex with the Ras protein (preliminary binding), which positions the electrophilic warhead for subsequent covalent bond formation. This preliminary non-covalent interaction ensures selectivity by requiring initial recognition of the target, while the final covalent bond provides prolonged duration of action.
Solution Approach 2:
The dual-mechanism binding (non-covalent followed by covalent) ensures continuous and sustained inhibition of K-Ras activity. The non-covalent interaction provides initial specificity, while the covalent bond maintains continuous inhibition over time, preventing the protein from recovering its active conformation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These covalent modulators effectively reduce the activity of K-Ras proteins, providing a potential therapeutic approach for treating cancers associated with K-Ras mutations by inhibiting the protein's signaling pathway.
Implementation Method 1
the use of covalent modulators, including reversible or irreversible compounds, to target and modulate the K-Ras protein
Data Source
AI summary
Provided herein, inter alia, are methods and compounds for inhibiting K-Ras and for treating cancer.